What Is Rusfertide? The Hepcidin-Mimetic Peptide Now Approved for Polycythaemia Vera

Not all modern peptide development is focused on obesity, muscle or ageing.

One of the most interesting recent examples comes from haematology.

Rusfertide is a synthetic hepcidin-mimetic peptide designed to regulate how iron is distributed in the body and, in turn, reduce excessive red blood cell production.

After years of clinical development, rusfertide reached a major milestone in 2026.

On 28 August 2026, the US Food and Drug Administration approved rusfertide under the brand name Mimrylo for the treatment of erythrocytosis in adults with polycythaemia vera. (U.S. Food and Drug Administration⁠)

That makes rusfertide a particularly useful example of how peptide research can progress from experimental biology all the way to an approved medicine.

What Is Rusfertide?

Rusfertide, previously known as PTG-300, is a synthetic peptide designed to mimic the biological actions of the hormone hepcidin.

Hepcidin is one of the body’s main regulators of iron metabolism.

Rusfertide is administered by subcutaneous injection once weekly.

Its role is not to destroy red blood cells directly.

Instead, it changes how much iron is available for the production of new red blood cells.

What Is Hepcidin?

Hepcidin is a naturally occurring peptide hormone produced mainly by the liver.

Its primary role is controlling the amount of iron circulating in the bloodstream.

It does this by interacting with a protein called ferroportin.

Ferroportin helps move iron:

• from intestinal cells into the blood
• from stored iron reserves into circulation
• from macrophages back into the bloodstream

When hepcidin levels rise, ferroportin activity falls.

The result is that less iron becomes available in the circulation.

Why Does Iron Matter for Red Blood Cell Production?

Red blood cells require iron to manufacture haemoglobin.

Haemoglobin is the protein responsible for carrying oxygen.

Without sufficient available iron, the bone marrow cannot produce large quantities of red blood cells efficiently.

Rusfertide uses this biological relationship deliberately.

By mimicking hepcidin, it reduces iron availability to the bone marrow and thereby helps limit excessive red blood cell production.

What Is Polycythaemia Vera?

Polycythaemia vera, commonly abbreviated to PV, is a chronic blood cancer in which the bone marrow produces too many blood cells, particularly red blood cells.

This can cause the blood to become more viscous.

Excessive red blood cell production can increase the risk of serious complications including:

• blood clots
• stroke
• heart attack
• other cardiovascular events

A major treatment goal is therefore to maintain the haematocrit below 45%. (U.S. Food and Drug Administration⁠)

What Is Haematocrit?

Haematocrit is the proportion of blood made up of red blood cells.

For example, a haematocrit of 45% means that approximately 45% of the blood volume consists of red blood cells.

In people with polycythaemia vera, keeping haematocrit below 45% is important because higher levels are associated with increased thrombotic risk.

How Has Polycythaemia Vera Traditionally Been Managed?

One of the oldest and most commonly used treatments is phlebotomy.

This involves removing blood from the body in much the same way as donating blood.

Removing blood directly lowers the number of circulating red blood cells and therefore reduces haematocrit.

Some patients require repeated phlebotomies over many years.

Other treatments may include drugs such as:

• hydroxyurea
• interferon
• ruxolitinib

depending on the individual patient’s risk factors and disease characteristics.

What Is the Problem With Repeated Phlebotomy?

Phlebotomy works, but it can create a significant treatment burden.

Patients may need repeated appointments whenever their haematocrit rises.

Frequent blood removal can also contribute to iron deficiency.

Interestingly, iron deficiency partly helps suppress red blood cell production, so clinicians often tolerate some degree of iron depletion in PV.

Rusfertide approaches the same problem in a more targeted way by directly controlling iron availability through the hepcidin pathway.

How Does Rusfertide Work?

Rusfertide acts as a hepcidin mimetic.

In practical terms, it reproduces key biological effects of natural hepcidin.

By limiting the amount of circulating iron available for haemoglobin production, rusfertide reduces the bone marrow’s ability to continuously produce excessive numbers of red blood cells.

This helps stabilise haematocrit without relying solely on repeated blood removal.

The FDA specifically described Mimrylo as the first approved treatment for polycythaemia vera that mimics hepcidin. (U.S. Food and Drug Administration⁠)

What Was the VERIFY Trial?

The pivotal Phase 3 study supporting approval was called VERIFY.

VERIFY was a global, randomised, double-blind, placebo-controlled Phase 3 trial.

It enrolled 293 adults with polycythaemia vera who continued to require frequent phlebotomy despite existing standard-of-care treatment. (ClinicalTrials⁠)

Participants received either:

• rusfertide
• or placebo

in addition to their existing treatment.

What Was the Main Goal of the Trial?

Researchers wanted to determine whether rusfertide could maintain haematocrit control sufficiently well that participants no longer met criteria for phlebotomy.

The primary analysis focused on weeks 20 to 32.

A clinical response meant that the participant maintained adequate haematocrit control without becoming eligible for another phlebotomy.

What Did the Phase 3 Results Show?

The difference between rusfertide and placebo was substantial.

During the primary evaluation period:

76.9% of participants receiving rusfertide achieved a clinical response

compared with

32.9% receiving placebo. (Takeda Pharmaceuticals⁠)

Rusfertide also significantly improved haematocrit control and reduced the need for phlebotomy.

Did Rusfertide Affect Symptoms?

Yes.

The VERIFY programme also evaluated patient-reported outcomes.

Takeda reported improvements in fatigue alongside better haematocrit control and reduced phlebotomy requirements. (Takeda Pharmaceuticals⁠)

This matters because polycythaemia vera can produce symptoms including:

• fatigue
• headaches
• dizziness
• itching
• problems with concentration

Treatment success therefore involves more than simply changing a laboratory number.

How Is Rusfertide Administered?

The approved US treatment is given by subcutaneous injection once weekly.

The FDA-approved starting dose is 19 mg once weekly, with subsequent dose adjustment based on efficacy and safety. (Access Data⁠)

This is prescription treatment under medical supervision.

What Were the Most Common Side Effects?

According to the FDA-approved prescribing information, the most commonly reported adverse reactions included:

• injection-site reactions
• anaemia

Injection-site reactions occurred particularly frequently in the clinical programme. (Access Data⁠)

Because rusfertide intentionally restricts iron availability, excessive suppression of red blood cell production is an important safety consideration.

Why Can Anaemia Occur?

The therapeutic goal is to reduce excessive red blood cell production.

But if iron availability becomes too restricted, red blood cell production can potentially fall too far.

That may lead to anaemia.

This illustrates an important point about peptide therapies:

the same biological mechanism responsible for the desired effect can also produce adverse effects if pushed too far.

Is Rusfertide Still Being Studied?

Yes.

Although the drug is now approved in the US, longer-term follow-up continues.

The VERIFY trial includes extended treatment periods designed to investigate durability of haematocrit control and long-term safety. (ClinicalTrials⁠)

Takeda has also stated that it is working with regulators outside the United States. (Takeda Pharmaceuticals⁠)

Why Is Rusfertide Scientifically Interesting?

Rusfertide is unusual because it does not simply block a receptor or stimulate a conventional growth pathway.

It essentially recreates the action of one of the body’s own iron-regulating hormones.

The treatment therefore works through a chain of biological events:

hepcidin signalling

↓

reduced ferroportin-mediated iron availability

↓

less iron available for haemoglobin production

↓

reduced excessive red blood cell production

↓

better haematocrit control

This is a very different therapeutic strategy from most of the peptides commonly discussed online.

Is Rusfertide a Genuine Peptide Drug?

Yes.

Rusfertide is a synthetic hepcidin-mimetic peptide.

It was originally discovered by Protagonist Therapeutics and later developed and commercialised globally by Takeda. (Takeda Pharmaceuticals⁠)

Its successful development also demonstrates that peptide drugs can be engineered to reproduce complex hormone biology with sufficient stability for practical once-weekly dosing.

How Is This Different From Peptides Sold Through Research Markets?

This distinction is important.

Rusfertide progressed through:

• preclinical research
• Phase 1 studies
• Phase 2 studies
• a randomised Phase 3 trial
• regulatory review
• FDA approval

That process involved detailed evaluation of:

• pharmacokinetics
• pharmacodynamics
• dose selection
• clinical efficacy
• manufacturing
• safety
• long-term monitoring

This is very different from experimental peptides that have only animal evidence or no published human research.

Why Did the FDA Consider Rusfertide Important?

The FDA described rusfertide as a first-in-class treatment targeting the underlying biology responsible for red blood cell overproduction in PV. (U.S. Food and Drug Administration⁠)

The agency also highlighted its potential to reduce the burden of repeated phlebotomy.

The drug received Priority Review before its approval.

Is Rusfertide Approved in the UK?

The August 2026 approval applies specifically to the United States.

Regulatory authorisation differs between jurisdictions.

A US FDA approval should therefore not be interpreted as automatic approval or routine availability in the UK.

Takeda has stated that it is working with regulators outside the US. (Takeda Pharmaceuticals⁠)

What Makes Rusfertide Different From Most Peptides in Our Research Hub?

Many compounds we have covered sit somewhere on a spectrum from:

interesting preclinical science

to

early human research

to

Phase 2 or Phase 3 development.

Rusfertide has crossed the entire pathway into regulatory approval.

That makes it useful as a benchmark.

It demonstrates what the evidence base behind a fully developed peptide medicine eventually looks like.

What Can Rusfertide Teach Us About Peptide Research?

There is an important broader lesson.

A biologically interesting mechanism is only the beginning.

Rusfertide’s path required years of work establishing:

• whether the molecule reached its target
• whether its effects were predictable
• appropriate dosing
• long-term haematocrit control
• reduction in phlebotomy requirements
• safety
• patient-reported benefits

This is why early animal findings should never be treated as equivalent to clinical proof.

The Bottom Line

Rusfertide is a synthetic hepcidin-mimetic peptide designed to control excessive red blood cell production by limiting the availability of iron required for haemoglobin synthesis.

In the Phase 3 VERIFY trial involving 293 adults with polycythaemia vera, 76.9% of patients receiving rusfertide achieved the study’s clinical response compared with 32.9% receiving placebo. (U.S. Food and Drug Administration⁠)

On 28 August 2026, the FDA approved rusfertide under the brand name Mimrylo for erythrocytosis in adults with polycythaemia vera. (U.S. Food and Drug Administration⁠)

That makes rusfertide one of the clearest recent examples of a peptide moving from experimental hormone mimicry to an approved medical therapy.

It also shows how broad modern peptide research has become.

Peptides are no longer confined to metabolic hormones, muscle research or experimental recovery compounds.

They are increasingly being engineered to manipulate highly specific biological systems — including something as fundamental as how the human body controls iron.

This article is for research and educational purposes only and does not constitute medical advice. Regulatory approval and availability vary by country.